Get the Stockscreener App
1.95
3.26%
0.0615
Immuron Limited Adr stock is traded at $1.95, with a volume of 6,952.
It is up +3.26% in the last 24 hours and down -0.51% over the past month.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
See More
Previous Close:
$1.8885
Open:
$1.9
24h Volume:
6,952
Relative Volume:
0.98
Market Cap:
$10.26M
Revenue:
$2.35M
Net Income/Loss:
$-2.56M
P/E Ratio:
-4.4359
EPS:
-0.4396
Net Cash Flow:
-
1W Performance:
+1.04%
1M Performance:
-0.51%
6M Performance:
-16.33%
1Y Performance:
+2.87%
1-Day Range:
$1.82
$1.96
1-Week Range:
$1.80
$2.00
52-Week Range:
$1.59
$5.96
Immuron Limited Adr Stock (IMRN) Company Profile
Compare IMRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| IMRN | 1.90 | 10.26M | 2.35M | -2.56M | 0 | -0.4396 |
| VRTX | 447.19 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.49 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.59 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.27 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.48 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Immuron Limited Adr Stock (IMRN) Latest News
Immuron to Present at Q4 Virtual Investor Summit: Gut Disease Pipeline Showcase | IMRN Stock News - StockTitan
Immuron Travelan® continued strong sales growth - Quantisnow
NMRC Reports Results for Campylobacter Controlled Human Infection Model Study - The Manila Times
IMRNImmuron Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
Immuron Plans Phase 2 Trial for IMM-529 following FDA review - Markets Insider
Immuron Plans Phase 2 Trial for IMM-529 following FDA review | Daily Guardian - Daily Guardian Canada
Immuron secures new US DoD research award - Investing.com
Immuron secures new US DoD research award By Investing.com - Investing.com Australia
Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan® - GlobeNewswire Inc.
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now - GlobeNewswire Inc.
Treasuries slip, dollar firm as markets grapple with US politics By Reuters - Investing.com
Curtiss Wright CEO Lynn M Bamford buys $10.2k in stock By Investing.com - Investing.com India
Immuron CEO to present at Sharewise investor event By Investing.com - Investing.com
Immuron to raise up to $2M as part of an ATM equity offering (NASDAQ:IMRN) - Seeking Alpha
Immuron secures around US$2 million in funding after lodging Form F-3 and ATM prospectus with US SEC By ... - Investing.com
Immuron requests pre-IND meeting for IMM-529 with FDA filing - Markets Insider
Immuron requests pre-IND meeting for IMM-529 with FDA filing | Daily Guardian - Daily Guardian Canada
Immuron files pre-investigational new drug US FDA application for superbug fighting IMM-529 - Proactive Investors Australia
Immuron Surges On U.S. DoD Funding For Travelan Research - Yahoo Movies UK
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.34% - MSN
Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket - Markets Insider
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.34% - Investing.com India
Immuron stock surges after mid-stage data for Travelan - Seeking Alpha
Check Up: These 4 ASX healthcare stocks come with Strong Buy recommendations - Stockhead
Check Up: Immuron wins big in US and Europe on travellers’ diarrhoea drug - Stockhead
Check Up: As Alzheimer’s grabs the spotlight, these ASX biotech stocks also impressed - Stockhead
45 Stocks Moving in Tuesday's Pre-Market SessionArbutus Biopharma (NASDAQ:ABUS), ACADIA Pharmaceutical - Benzinga
36 Stocks Moving in Monday's Pre-Market Session - Benzinga
The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortf - Benzinga
58 Biggest Movers From YesterdayArbutus Biopharma (NASDAQ:ABUS), Acer Therapeutics Inc (OTC:ACER) - Benzinga
IMMURON LIMITED - ShareCafe
Immuron Limited Trade Ideas — NASDAQ:IMRN - TradingView
29 Stocks Moving In Wednesday's Mid-Day SessionBabcock & Wilcox (NYSE:BW), AstroNova (NASDAQ:ALOT) - Benzinga
35 Stocks Moving In Tuesday's Mid-Day SessionAyala Pharmaceuticals (OTC:ADXS) - Benzinga
Immuron Limited Issues Correction to Misleading Halt Announcement Headline - GlobeNewswire
Pharma & Biotech - Proactive Investors USA
Immuron Limited Adr Stock (IMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):